Clinical trials: Adenocarcinoma of the Prostate
Prostate Neoplasms
PS-341 Followed by Removal of Prostate for Those With Prostate Cancer
Following pretreatment evaluation, patients receive PS-341 by intravenous push weekly for 4 consecutive weeks followed by a 24-72 hour rest period. This schedule consists of one treatment cycle.
- Trial name
- NCT00425503
- Testing
- PS-341 (bortezomib)
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Baylor College of Medicine
Small Cell Lung Cancer Metastatic or Locally Advanced, Neuroendocrine Cancer
Evaluating BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine Tumors
The objective of this study is to evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of BL-M14D1 in Subjects with locally Advanced or Metastatic Small Cell Lung Cancer and Other Neuroendocrine Neoplasms
- Conditions
- Small Cell Lung Cancer Metastatic or Locally Advanced, Neuroendocrine Cancer, Metastatic Neuroendocrine Prostate Cancer, Metastatic Advanced Poorly Differentiated Gastroenteropancreatic Neuroendocrine Carcinoma
- Trial name
- NCT07080242
- Testing
- BL-M14D1
- Where
- 31 sites in United States, Georgia and 1 more
- Volunteers
- 120 people
- Sponsor
- SystImmune Inc.
Prostate Cancer
Triptorelin and Radiation Therapy in Treating Patients Who Have Undergone Surgery for Intermediate-Risk Stage III or Stage IV Prostate Cancer
RATIONALE: Androgens can cause the growth of prostate cancer cells. Antihormone therapy, such as triptorelin, may lessen the amount of androgens made by the body. Radiation therapy uses high-energy x-rays to kill tumor cells.
- Trial name
- NCT00667069
- Testing
- triptorelin, adjuvant therapy, 3-dimensional conformal radiation therapy
- Where
- 17 sites in France
- Volunteers
- 424 people
- Sponsor
- UNICANCER
Prostatic Neoplasms
Study to Evaluate the Safety and Tolerability of CC-94676 in Participants With Metastatic Castration-Resistant Prostate Cancer
The purpose of this study is to assess the safety, tolerability and preliminary efficacy of CC-94676 in men with progressive metastatic castration resistant prostate cancer.
- Trial name
- NCT04428788
- Testing
- CC-94676, CC1083611, CC1083610
- Where
- 19 sites in United States
- Volunteers
- 131 people
- Sponsor
- Celgene
Prostate Cancer
Hormone Therapy Plus Chemotherapy in Treating Patients With Prostate Cancer
RATIONALE: Androgens can stimulate the growth of prostate cancer cells. Drugs such as luteinizing hormone-releasing hormone agonist, flutamide, and bicalutamide may stop the adrenal glands from producing androgens.
- Trial name
- NCT00030654
- Testing
- bicalutamide, docetaxel, doxorubicin hydrochloride
- Where
- 78 sites in United States, Australia and 2 more
- Volunteers
- 21 people
- Sponsor
- Radiation Therapy Oncology Group
Prostate Adenocarcinoma
Strategic Endocrine Therapy and Targeted Radiotherapy for Prostate Cancer
The goal of this clinical trial is to study definitive external beam radiation therapy together with drugs called androgen deprivation therapy (ADT) in patients with prostate cancer.
- Trial name
- SENTRY (NCT07364071)
- Testing
- Radiation therapy
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- University of California, San Diego
Motor Function, Cognitive Function
Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years
This study is a postmarketing requirement jointly carried out by four NDA holders (Bayer AG, Bracco, GE Healthcare and Guerbet) and the CRO IQVIA.
- Conditions
- Motor Function, Cognitive Function, Contrast Media
- Trial name
- ODYSSEY (NCT04373564)
- Testing
- Motor Tests, Cognitive Tests, Unenhanced-MRI of the brain
- Where
- 51 sites in United States, Brazil and 6 more
- Volunteers
- 2,076 people
- Sponsor
- Guerbet
Prostate Cancer Adenocarcinoma
Intratumoral Microbiota and Immune Microenvironment in Prostate Cancer
Prostate cancer is a common malignancy in men, with rising incidence worldwide. Current clinical risk assessment tools-including PSA, Gleason score/ISUP grade, pathological stage, margin status, perineural invasion, and…
- Trial name
- NCT07818421
- Testing
- Validate spatial localization of candidate microbial signals via 16S rRNA ISH, FISH, immunofluorescence, IHC, and spatial omics.
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Anhui Medical University
Metastatic Cancer, Prostate Cancer
Biomarkers of Response to Taxotere in HRPC. ICORG 08-08, V2
RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT01160705
- Testing
- docetaxel, RNA analysis, reverse transcriptase-polymerase chain reaction
- Where
- 5 sites in Ireland
- Volunteers
- 73 people
- Sponsor
- Cancer Trials Ireland
Prostate Adenocarcinoma, Stage I Prostate Cancer AJCC v8
Neoadjuvant Dietary Intervention in Intermediate Risk Prostate Cancer
This clinical trial studies the effects of a dietary intervention prior to surgery (neoadjuvant) in patients with intermediate risk prostate cancer. Changing your diet before surgery may help to improve overall health.
- Conditions
- Prostate Adenocarcinoma, Stage I Prostate Cancer AJCC v8, Stage II Prostate Cancer AJCC v8, Stage IIA Prostate Cancer AJCC v8
- Trial name
- NCT04985565
- Testing
- Dietary Intervention, Radical Prostatectomy
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- M.D. Anderson Cancer Center
Metastatic Prostate Adenocarcinoma, Stage IV Prostate Cancer AJCC v8
Vidutolimod (CMP-001) in Combination With Nivolumab for the Treatment of Metastatic Castration Resistant Prostate Cancer
This phase II trial tests whether vidutolimod with nivolumab works to destroy tumor cells in patients with castration resistant prostate cancer that has spread to other places in the body (metastatic).
- Trial name
- NCT05445609
- Testing
- VLP-encapsulated TLR9 Agonist CMP-001,, Nivolumab
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Emory University
Prostate Cancer
Celecoxib Compared With No Treatment Before Surgery in Treating Patients With Localized Prostate Cancer
RATIONALE: Celecoxib may be an effective treatment for early stage prostate cancer. It is not yet known if celecoxib is more effective than no treatment before surgery for prostate cancer.
- Trial name
- NCT00022399
- Testing
- celecoxib
- Where
- United States
- Volunteers
- 73 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Prostate Cancer
C-11 Choline PET-CT Scan in Finding Metastases in Patients With Newly Diagnosed High-Risk Prostate Cancer
RATIONALE: New diagnostic procedures, such as C-11 choline PET-CT scan, may be effective in finding cancer that has spread to the bone and lymph nodes in patients with prostate cancer.
- Trial name
- NCT00804245
- Testing
- needle biopsy, PET-CT scans supplemented with 11C-Choline tracer
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Wake Forest University Health Sciences
Prostate Cancer
Selenium in Treating Patients With Prostate Cancer
RATIONALE: Selenium may prevent or slow the growth of prostate cancer. PURPOSE: This randomized phase II trial is studying how well selenium works in treating patients with prostate cancer.
- Trial name
- NCT00752739
- Testing
- selenium
- Where
- United States
- Volunteers
- 220 people
- Sponsor
- University of Arizona
Prostate Adenocarcinoma, Stage IIA Prostate Cancer
Degarelix Acetate Before and During Radiation Therapy in Treating Patients With Prostate Cancer
This pilot clinical trial studies how well degarelix acetate before and during radiation therapy works in treating patients with prostate cancer. Androgens can cause the growth of prostate cancer cells.
- Conditions
- Prostate Adenocarcinoma, Stage IIA Prostate Cancer, Stage IIB Prostate Cancer, Stage III Prostate Cancer
- Trial name
- NCT01731912
- Testing
- Degarelix, External Beam Radiation Therapy, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- University of Washington
Prostate Adenocarcinoma, Stage III Prostate Cancer AJCC v8
Daratumumab or FMS Inhibitor JNJ-40346527 Before Surgery in Treating Patients With High-Risk, Resectable Localized or Locally Advanced Prostate Cancer
This phase I trial studies the side effects of daratumumab or FMS inhibitor JNJ-40346527 before surgery in treating patients with high-risk prostate cancer that can be removed by surgery and has not spread to other parts of the…
- Conditions
- Prostate Adenocarcinoma, Stage III Prostate Cancer AJCC v8, Stage IIIA Prostate Cancer AJCC v8, Stage IIIB Prostate Cancer AJCC v8
- Trial name
- NCT03177460
- Testing
- Daratumumab, FMS Inhibitor JNJ-40346527, Radical Prostatectomy
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- M.D. Anderson Cancer Center
Metastatic Prostate Cancer
Study of HLD-0915 (JNJ-101556143) in Patients With Metastatic Prostate Cancer
Assessment of the safety and efficacy of HLD-0915 (JNJ-101556143) in patients with metastatic prostate cancer who have progressed on prior systemic therapies, with further evaluation in additional prostate cancer populations.
- Trial name
- NCT06800313
- Testing
- JNJ-101556143 Formulation 1, JNJ-101556143 Formulation 2, JNJ-101556143 Formulation 3
- Where
- 18 sites in United States, United Kingdom
- Volunteers
- 190 people
- Sponsor
- Janssen Research & Development, LLC
Hormone-Resistant Prostate Cancer, Metastatic Prostate Carcinoma
Cell-Free DNA and RNA in Blood fromMetastatic Prostate Cancer Patients
This research trial studies cell-free deoxyribonucleic acid (DNA) and ribonucleic acid (RNA) in blood from patients with prostate cancer that does not respond to hormone therapy and has spread to other places in the body.
- Conditions
- Hormone-Resistant Prostate Cancer, Metastatic Prostate Carcinoma, Prostate Adenocarcinoma
- Trial name
- NCT02853097
- Testing
- Cytology Specimen Collection Procedure, Laboratory Biomarker Analysis
- Where
- 3 sites in United States
- Volunteers
- 7 people
- Sponsor
- University of Southern California
Advanced Adult Primary Liver Cancer, Anaplastic Thyroid Cancer
Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu
Interleukin-12 may kill tumor cells by stopping blood flow to the tumor and by stimulating a person's white blood cells to kill cancer cells.
- Conditions
- Advanced Adult Primary Liver Cancer, Anaplastic Thyroid Cancer, Bone Metastases, Carcinoma of the Appendix
- Trial name
- NCT00004074
- Testing
- recombinant interleukin-12, ABI-007/carboplatin/trastuzumab
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- National Cancer Institute (NCI)
Prostate Cancer
PROSTVAC®-VF/TRICOM™ Vaccine for the Treatment of Metastatic Prostate Cancer After Failing Hormone Therapy
PROSTVAC-VF is an investigational cancer vaccine. The vaccine is based on the theory that the immune system can be taught to fight cancer by directing the immune system to attack specific targets found on cancer cells.
- Trial name
- NCT00078585
- Testing
- PROSTVAC®-VF/TRICOM™
- Where
- 47 sites in United States
- Volunteers
- 120 people
- Sponsor
- Bavarian Nordic